Observation of the Immune Response After COVID-19 Additional Vaccine Doses in Chronic Patients in Hemodialysis Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

23 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-25

Study Completion Date

2022-09-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observation of humoral and cellular immune response after additional dose vaccine with different COVID-19 vaccines in ESKD patients in hemodialysis therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immune Response of Haemodialysis Patients Post Covid-19 Vaccination

NCT04872751

Immune Response Post Covid 19 Vaccination

UNKNOWN

Assessment of Immune Response After Vaccination Against COVID-19 in Patients Treated With Renal Replacement Therapy

NCT04905862

Kidney Failure, Chronic Covid19 Vaccine Reaction +1 more

UNKNOWN

The REnal Patients COVID-19 VACcination Immune Response (RECOVAC IR) Study

NCT04741386

Covid19 Chronic Kidney Diseases

COMPLETED

Registry of Sustained Immunity to COVID-19 Among ESKD Patients

NCT04495764

SARS-CoV-2 Infection Anti-SARS-CoV-2 Infection

COMPLETED

RECOVAC - Long Term Efficacy and Safety of COVID-19 (SARS-CoV-2) Vaccination in Kidney Disease Patients

NCT04841785

Covid19 SARS-CoV Infection Chronic Kidney Diseases

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this open, prospective, observational trial the humoral and cellular immune response in ESKD patients undergoing hemodialysis shall be analyzed after administration of a fourth dose of vaccine. The total follow-up time per patient is up to 12 months after the fourth dose of vaccine.

In total, 340 patients (170 patients per country) shall be included. Only adult patients capable of giving consent will be enrolled. The humoral immune response will be analyzed in all patients, whereas the analysis of the cellular immune response will only be conducted in 15% of the enrolled patients.

The HD-COVID-IR-EU study shall be conducted in Portugal and in Spain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Diseases COVID-19 Hemodialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood samples

Four consecutive blood sampling throughout the overall follow-up period of 12 months.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent signed and dated by study patient and investigator/authorized physician
* Minimum age of 18 years
* Ability to understand the nature and requirements of the study
* ESKD patients on maintenance hemodialysis with a minimum of 4hrs three times a week at the time of recruitment and a dialysis vintage ≥3 months in NC clinics
* Patients that already received three doses against COVID-19 as detailed in the manufacturer's instructions
* Patients that are scheduled to receive a fourth vaccine dose of either Comirnaty (BioNTech/Pfizer) or Spikevax (Moderna) after approval of respective national authority.

Exclusion Criteria

* Any conditions which could interfere with the patient's ability to comply with the study
* Participation in an interventional clinical study during the preceding 30 days
* Previous participation in the same study
* Patients with proven current COVID-19 infection as identified by routine clinical practice
* Patient in therapy with immunosuppressive medications / immunomodulators
* Patients who already received a fourth COVID-19 vaccination dose

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No